Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) has been given an average recommendation of “Moderate Buy” by the three ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target […]
Jefferies Financial Group began coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) in a report issued on Friday, The Fly reports. The brokerage issued a buy rating on the stock. Other equities analysts have also issued research reports about the company. William Blair lowered Praxis Precision Medicines from an outperform rating to […]
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 5,970,000 shares, an increase of 34.2% from the March 15th total of 4,450,000 shares. Approximately 14.4% of the company’s shares are sold short. […]
HC Wainwright reiterated their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) in a research report sent to investors on Friday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock. Separately, William Blair lowered shares of Praxis Precision Medicines from an outperform rating to a market […]
Praxis Precision Medicines (NASDAQ:PRAX – Get Rating)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $16.00 price target on the stock. Separately, William Blair downgraded shares of Praxis Precision Medicines from an “outperform” rating to a “market perform” rating in a […]